Friday - March 14, 2025
MD Anderson and Myriad Genetics Form Strategic Alliance to Evaluate Clinical Utility of Myriad's Molecular Residual Disease Assay
January 08, 2025
HOUSTON, Texas, Jan. 8 (TNSres) -- The University of Texas MD Anderson Cancer Center issued the following news release on Jan. 7, 2024:

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease (MRD) assay.

This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Geneti . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products